Symbiomix
AcquiredNewark, United States · Founded 2012 · $41.0M raised
- Headquarters
- Newark
- Founded
- 2012
- Business Model
- B2B
- Website
- symbiomix.com
- Total Funding
- $41.0M
- Last Round
- $41.0M Series AMay 2015
- Rounds
- 2
- Acquisition Date
- Oct 2017
About
Symbiomix Therapeutics was a Newark, New Jersey-based late-stage biopharmaceutical company founded in 2012 that developed medicines for neglected women's health infections. Its lead candidate, SYM-1219 (secnidazole), won FDA approval in 2017 as Solosec, the first single-dose oral treatment for bacterial vaginosis in adult women. Backed by OrbiMed, Fidelity Biosciences, and HBM Partners, Symbiomix closed a $41 million financing round before being acquired by India's Lupin Limited for $150 million in October 2017.
Summary
Symbiomix is a Biotech company based in Newark, United States, founded in 2012. It has raised $41.0M in total across 2 rounds, most recently a $41.0M Series A round in May 2015. Investors include OrbiMed, Lupin and HBM Healthcare Investments.
Funding History
Oct 2017
Sign up to see all 3 rounds
Venture Round through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/symbiomix"><img src="https://indexed.vc/api/badge/company/symbiomix" alt="Symbiomix on Indexed.vc" width="260" height="76" /></a>